Pharma Capsules - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharma Capsules
Brief pharmaceutical news items for February 2008.

Pharmaceutical Technology


Agreements

DSM Signs Supply Agreement with IEP

DSM Pharma Chemicals (Parsippany, NJ), a business unit of DSM Pharmaceutical Products, entered into an enzyme- supply agreement with IEP (Wiesbaden, Germany) to enable fast and secure scale-up of chiral alcohol manufacturing. Under the terms of the agreement, DSM Pharma Chemicals has access to IEP's alcohol dehydrogenases, as well as a supply of IEP enzymes at commercial scale. DSM can source the enzymes from IEP or produce them in its own manufacturing facilities in Delft, The Netherlands, Capua, Italy, and Seclin, France. According to Oliver May, DSM's competence manager for biocatalysis, a flexible enzyme supply chain is key to the timely delivery of products to DSM's customers.

Akrimax Purchases Wyeth Plant

Akrimax Pharmaceuticals (Cranford, NJ) acquired Wyeth's (Madison, NJ) drug-product manufacturing and packaging plant in Rouses Point, New York. The acquisition prevents the plant's closure. Wyeth had planned to phase out its operations at the Rouses Point plant because of changes in product demand and a reassessment of its manufacturing network.

Akrimax is an emerging branded-pharmaceutical company led by a management team with expertise in the development, manufacturing, distribution, marketing, and sales of pharmaceutical products.


ADVERTISEMENT

RELATED CONTENT
Pharma Capsules
Pharma Capsules
Pharma Capsules
Pharma Capsules
Pharma Capsules
blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here